Cite
Moyo-Gwete T, Madzivhandila M, Makhado Z, et al. SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies. bioRxiv. 2021;doi: 10.1101/2021.03.06.434193.
Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B. E., Kgagudi, P., Tegally, H., Iranzadeh, A., Doolabh, D., Tyers, L., Chinhoyi, L. R., Mennen, M., Skelem, S., Marais, G., Wibmer, C. K., Bhiman, J. N., Ueckermann, V., Rossouw, T., Boswell, M., de Oliveira, T., Williamson, C., Burgers, W. A., Ntusi, N., Morris, L., & Moore, P. L. (2021). SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.03.06.434193
Moyo-Gwete, Thandeka, et al. "SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.03.06.434193
Moyo-Gwete T, Madzivhandila M, Makhado Z, Ayres F, Mhlanga D, Oosthuysen B, Lambson BE, Kgagudi P, Tegally H, Iranzadeh A, Doolabh D, Tyers L, Chinhoyi LR, Mennen M, Skelem S, Marais G, Wibmer CK, Bhiman JN, Ueckermann V, Rossouw T, Boswell M, de Oliveira T, Williamson C, Burgers WA, Ntusi N, Morris L, Moore PL. SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies. bioRxiv. 2021 Mar 11; doi: 10.1101/2021.03.06.434193. PMID: 33688657; PMCID: PMC7941631.
Copy
Download .nbib